Table 2.
Bone markers in patients treated with Dmab (BP-naïve and BP-prior) and BP treated patients not switched to Dmab (control group).
| Basal | 12 m | Change (%) | |
|---|---|---|---|
| BP-naïve | |||
| tAP (IU/L) | 160.60 ± 16.32 | 113.50 ± 11.28# | ↓29.33 |
| BGP (ng/mL) | 26.78 ± 3.15& | 20.22 ± 3.11# | ↓24.50 |
| s-CTX (ng/L) | 509.80 ± 54.66& | 101.40 ± 30.55# | ↓80.11 |
|
| |||
| BP-prior | |||
| tAP (IU/L) | 146.00 ± 010.21 | 117.90 ± 8.32∗ | ↓19.25 |
| BGP (ng/mL) | 19.58 ± 1.06 | 10.53 ± 0.65∗ | ↓46.22 |
| s-CTX (ng/L) | 314.90 ± 17.47 | 101.20 ± 9.00∗ | ↓67.86 |
|
| |||
| Control group | |||
| tAP (IU/L) | 147.90 ± 7.01 | 141.30 ± 6.63 | ns |
| BGP (ng/mL) | 17.37 ± 2.00 | 16.08 ± 1.28 | ns |
| s-CTX (ng/L) | 275.60 ± 28.67 | 204.00 ± 17.05θ | ↓25.98% |
#Significant differences with BP-naïve basal; &significant differences with BP-prior basal; ∗significant differences with BP-prior basal; θsignificant differences with control group basal.